Based on the results from preclinical experiments, IL-17A blockade is considered as a potential therapeutic approach for several types of CNS diseases, including MS (EAE) [19], ischemic brain injury [31, 32], and traumatic brain injury [33]. Here, IL17A is linked to myeloid sarcoma.